An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab
/L and observed no detriment with early TPE cessation. Additional high-quality studies re-evaluating daily TPE cessation endpoints are needed for patients with iTTP receiving caplacizumab.
Authors
- Jay S. Raval (ORCID: https://orcid.org/0000-0001-9835-957X)
- Grace M. Lee (ORCID: https://orcid.org/0000-0002-0051-2466)
- Erika Hochhaus
Institutions
- University of New Mexico (US)
- University of Vermont Medical Center (US)
- Duke Medical Center (US)
- Duke University Health System (US)
Publication Details
- Journal
- Journal of Clinical Apheresis
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1002/jca.70127
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00